Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» graft vs host disease
graft vs host disease
Ironwood spies new frontier for $1B GLP-2 analog in exploratory phase 2 rare disease trial
Fierce Biotech
Thu, 03/28/24 - 11:16 am
Ironwood Pharmaceuticals
apraglutide
VectaBio
graft vs host disease
Microbiome-based treatment shows potential in graft-versus-host disease
Biopharma Reporter
Tue, 12/19/23 - 10:16 am
MaaT Pharma
microbiome
graft vs host disease
MaaT013
Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting
BioSpace
Thu, 09/21/23 - 10:38 am
Mesoblast
remestemcel-L
FDA
graft vs host disease
FDA Blocks Mesoblast Cell Therapy Again, Asks for More Data
BioSpace
Sun, 08/6/23 - 09:34 pm
Mesoblast
remestemcel-L
FDA
graft vs host disease
cell therapy
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
After 20-month hold, FDA drops resistance to fecal pooling, clears MaaT to run pivotal trial
Fierce Biotech
Tue, 04/25/23 - 10:37 am
MaaT Pharma
FDA
clinical trials
fecal therapy
graft vs host disease
Takeda’s Vedolizumab Clears Phase III in aGvHD
BioSpace
Tue, 02/21/23 - 10:03 am
Takeda
vedolizumab
graft vs host disease
clinical trials
2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission
Fierce Biotech
Sun, 11/27/22 - 07:05 pm
Mesoblast
FDA
cell therapy
remestemcel-L
graft vs host disease
AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease
Fierce Pharma
Thu, 08/25/22 - 11:04 am
JNJ
AbbVie
Imbruvica
graft vs host disease
pediatric
FDA
FDA declines to free MaaT's microbiome drug from clinical hold after a year
Fierce Biotech
Wed, 08/10/22 - 11:31 pm
MaaT Pharma
FDA
microbiome
clinical trials
graft vs host disease
Sanofi's latest analysis of Rezurock can inform future research, company says
Fierce Pharma
Thu, 04/21/22 - 10:34 am
Sanofi
Kadmon
M&A
graft vs host disease
Rezurock
AbbVie files sNDA to FDA for chronic graft versus host disease therapy
Pharmaceutical Business Review
Tue, 03/1/22 - 10:24 am
AbbVie
Imbruvica
graft vs host disease
FDA
Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention
Reuters
Wed, 12/15/21 - 11:54 pm
Bristol Myers Squibb
Orencia
FDA
graft vs host disease
Incyte and Syndax to jointly develop and commercialize axatilimab
Pharmaceutical Business Review
Tue, 09/28/21 - 12:01 pm
Incyte
Syndax Pharma
axatilimab
graft vs host disease
Incyte on a Roll with Two FDA Wins in Two Days
BioSpace
Thu, 09/23/21 - 10:55 pm
Incyte
FDA
Jakafi
graft vs host disease
ruxolitinib
atopic dermatitis
Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug
Stat
Wed, 09/8/21 - 12:01 pm
Sanofi
Kadmon
M&A
transplant medicine
graft vs host disease
Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
Fierce Pharma
Mon, 07/19/21 - 11:04 am
Kadmon
Rezurock
graft vs host disease
FDA
belumodsil
FDA delays Kadmon’s priority review as apparent clampdown continues
Endpoints
Thu, 03/11/21 - 10:40 am
Kadmon
FDA
priority review
belumodsil
graft vs host disease
FDA to quickly review Incyte’s Jakafi in chronic GVHD
Pharmaforum
Tue, 02/23/21 - 10:42 am
FDA
Incyte
Jakafi
graft vs host disease
Orca-T Shows Preventative Potential for GVHS in High-Risk Blood Cancers
Targeted Oncology
Sun, 12/6/20 - 07:13 pm
Orca-T
HSCT
ASH2020
graft vs host disease
Pages
1
2
3
next ›
last »